Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06033963
Other study ID # SERIC-CASCEA
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 21, 2023
Est. completion date March 31, 2025

Study information

Verified date November 2023
Source The First Hospital of Jilin University
Contact Yi Yang, MD, PhD
Phone 0086-13756661217
Email doctor_yangyi@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to explore the safety and efficacy of remote ischemic conditioning in patients with carotid artery stenosis receiving carotid endarterectomy.


Description:

In this study, 100 patients with carotid artery stenosis receiving carotid endarterectomy are included in our center in China according to the principle of random, and parallel control. The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 6 consecutive days. The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day for 6 consecutive days. Two groups will be followed up for 90 days to evaluate the safety and efficacy of remote ischemic conditioning in patients with carotid artery stenosis receiving carotid endarterectomy.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date March 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Age=18 years, <80 years, regardless of sex; 2. Symptomatic or asymptomatic carotid artery stenosis. In symptomatic patients the degree of stenosis should more than 50% (Based on North American Symptomatic Carotid Endarterectomy Trial Collaborators (NASCET) Criteria), in asymptomatic patients the degree of stenosis should more than 70% (Based on NASCET Criteria); 3. Baseline mRS 0-2; 4. Can cooperate with and complete brain magnetic resonance imaging (MRI) examination; 5. Signed and dated informed consent is obtained; Exclusion Criteria: 1. Evolving stroke; 2. Chronic complete occlusion of the carotid artery without obvious symptoms of cerebral ischemia; 3. Severe dementia; 4. The causes of cardiogenic embolism, such as rheumatic mitral or aortic valve stenosis, artificial heart valves, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, left ventricular wall thrombosis or valve tumor, congestive heart failure, bacterial endocarditis, etc; 5. Uncontrolled hypertension (defined as systolic blood pressure = 180 mmHg or diastolic blood pressure = 110 mmHg, despite medication taken at enrollment); 6. Severe hepatic and renal dysfunction (defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =3 times higher than the upper limit of the normal range, creatinine >265umol/l (3mg/dl)); 7. The patients who have the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb. Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc; 8. Pregnant or lactating women; 9. He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission; 10. Other conditions that the researchers think are not suitable for the group.

Study Design


Intervention

Procedure:
Remote ischemic conditioning
Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
Sham remote ischemic conditioning
Remote ischemic conditioning (RIC) is induced by 5 cycles of 5 min of bilateral upper limbs ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.

Locations

Country Name City State
China The First Hospital of Jilin University Changchun Jilin

Sponsors (1)

Lead Sponsor Collaborator
Yi Yang

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients who got =1 new Diffusion Weighted Imaging (DWI)-positive lesions on post-treatment magnetic resonance imaging (MRI) Scans. Patients underwent magnetic resonance imaging (including DWI)at baseline and 6 days after randomization. 6 days
Secondary The number of new Diffusion Weighted Imaging (DWI)-positive lesions on post-treatment magnetic resonance imaging (MRI) Scans. Patients underwent magnetic resonance imaging (including DWI)at baseline and 6 days after randomization. 6 days
Secondary The volume of new Diffusion Weighted Imaging (DWI)-positive lesions on post-treatment magnetic resonance imaging (MRI) Scans. Patients underwent magnetic resonance imaging(including DWI) at baseline and 6 days after randomization. 6 days
Secondary Number of patients with cerebrovascular events, cardiovascular events or death. Cerebrovascular events included ischemic stroke, transient ischemic attack (TIA), cerebral hemorrhage. Cardiovascular events included angina and myocardial infarction. Death included any reason caused death. 90±7 days
Secondary Proportion of patients with any side effects of Remote ischemic conditioning (RIC) treatment. The side effects referred to any side effects of RIC or sham RIC treatment, not including the sides effect of medications and Carotid Endarterectomy (CEA). 6 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03931161 - Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1) Phase 4
Recruiting NCT03353103 - Imaging of Unstable Carotid Plaque in Patient Referred to Endarterectomy Phase 2
Completed NCT03996148 - Time to Post-Anesthesia Neurological Evaluation With Three Different Anesthetic Techniques Phase 4
Recruiting NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Completed NCT00597974 - Neurological Outcome With Carotid Artery Stenting N/A
Completed NCT00318851 - Carotid Artery Stenting With Protection Registry Phase 3
Active, not recruiting NCT05293067 - Troponin In Carotid Revascularization
Completed NCT03133429 - Clinical Study to Evaluate the Safety and Effectiveness of MER® Stents in Carotid Revascularisation. N/A
Recruiting NCT01440036 - The Correlation Between the Enzyme Paraoxigenase 1 (PON1) to Carotid Artery Atheromatous Plaque N/A
Completed NCT00417963 - ViVEXX Carotid Revascularization Trial (VIVA) Phase 3
Completed NCT00177346 - A Randomized Trial of Carotid Artery Stenting With and Without Cerebral Protection N/A
Recruiting NCT05574972 - Timing Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis(Timing Trial) N/A
Recruiting NCT02476396 - Structural Stability of Carotid Plaque and Symptomatology
Completed NCT05451485 - VFI in Healthy Vessels
Not yet recruiting NCT02224209 - Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis Phase 4
Completed NCT02006095 - Neuroimaging Correlates of Memory Decline Following Carotid Interventions
Terminated NCT01236508 - Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease Phase 4
Recruiting NCT05126238 - A Lithium-Based Medication to Improve Neurological Outcomes After Surgical Carotid Reconstruction Phase 3
Recruiting NCT06170580 - Improved Image Quality for Assessment of Carotid Artery Stenosis by Ultrafast Ultrasound FLOW Imaging
Recruiting NCT05800821 - Prediction of Cerebral Hyperperfusion Syndrome After Carotid Revascularization Using Deep Learning